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Antimicrobial resistance (AMR) is now a global threat. Its emergence rests on antimicrobial overuse in humans and
food-producing animals; globalization and suboptimal infection control facilitate its spread. While aggressive measures
in some countries have led to the containment of some resistant gram-positive organisms, extensively resistant
gram-negative organisms such as carbapenem-resistant enterobacteriaceae and pan-resistant Acinetobacter spp.
continue their rapid spread. Antimicrobial conservation/stewardship programs have seen some measure of success in
reducing antimicrobial overuse in humans, but their reach is limited to acute-care settings in high-income
countries. Outside the European Union, there is scant or no oversight of antimicrobial administration to
food-producing animals, while evidence mounts that this administration leads directly to resistant human
infections. Both horizontal and vertical infection control measures can interrupt transmission among humans, but
many of these are costly and essentially limited to high-income countries as well. Novel antimicrobials are urgently
needed; in recent decades pharmaceutical companies have largely abandoned antimicrobial discovery and
development given their high costs and low yield. Against this backdrop, international and cross-disciplinary
collaboration appears to be taking root in earnest, although specific strategies still need defining. Educational
programs targeting both antimicrobial prescribers and consumers must be further developed and supported. The
general public must continue to be made aware of the current scale of AMR’s threat, and must perceive
antimicrobials as they are: a non-renewable and endangered resource.
Keywords: Antimicrobial resistance, Antimicrobial conservation, Antibiotic stewardship, Infection control, Hand hygiene,
Surveillance networks, Care bundles, Environment, Regulations, Human medicine, Animal medicine, Global health, World
Healthcare-Associated Infections ForumBackground
There is nothing new under the sun, least of all anti-
microbial resistance (AMR) [1]. Microbes that are anti-
biotic producers have always needed to be resistant to
their own antibiotic. What is rapidly changing, however,
is the scale of this resistance and its impact on human
beings. Microbes have globalized along with their hosts,
while at the same time antimicrobial consumption by* Correspondence: didier.pittet@hcuge.ch
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stated.these hosts—both humans and animals—has exploded.
The gene pool for antimicrobial resistance has never
been so accessible, nor its selection pressure so strong.
Warnings of increased resistance are not new. Some
were issued prominently well before antimicrobials be-
came widely available. Alexander Fleming’s Nobel Prize
acceptance speech is often cited for his admonition that
“it is not difficult to make microbes resistant to penicil-
lin in the laboratory by exposing them to concentrations
not sufficient to kill them…there is the danger that the
ignorant man may easily under-dose himself and, by ex-
posing his microbes to nonlethal quantities of the drug,
make them resistant” [2].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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concern, the massive collateral resistance among the
myriad “bystander” organisms composing the human
microbiome was likely not anticipated [3]. Meanwhile,
the miracle drugs were transformative, both in reality
and in the psyche of millions (Figure 1). In 1954, the
USA produced just under 1 million kilograms of antimi-
crobials; annual production in this country alone now
exceeds 16 million kg [4]. The magic bullet described by
Paul Ehrlich had launched, and its life-saving trajectory
continues.
Our ability to develop and mass-produce over 25 classes
of antimicrobials in seventy years may seem monumental—
indeed, many hailed the new antibiotic era as the end of in-
fectious diseases. Unfortunately, the game is in fact rigged.
The infinitesimal generation time of a microbe will always
confer it the advantage: it has infinitely more opportunities
to gain resistance genes than we have to create new antimi-
crobials [5]. In this race, humans are being outrun: there
have been no successful discoveries of new classes of an-
tibiotics since 1987, while new, multi-resistant pathogens
such as carbapenem-resistant enterobacteriaceae (CRE) are
spreading with unprecedented alacrity [6].
The fourth biennial World Healthcare-Associated Infec-
tions Forum (WHAIF) met in June 2013 specifically to ad-
dress the rapid spread of AMR. Seventy world experts
from over thirty countries gathered in Annecy, France, to
present and discuss their various successes—and failures
—in the domain of AMR in order to better define futureFigure 1 An advertisement by Schenley Laboratories Inc.
By 1944, laboratories across the country were increasing penicillin
production. Schenley’s advertisement stated, "When the thunderous
battles of this war have subsided to pages of silent print in a history
book, the greatest news event of World War II may well be the
discovery and development of penicillin." Credit: Research and
Development Division, Schenley Laboratories Inc., Lawrenceburg,
Indiana, USA.strategies to meet its challenge. In this position paper, we
summarize the Forum’s key messages and conclusions.
AMR’s increasing prevalence
Just three years after Fleming’s warning, 38% of
Staphylococcus aureus strains in one London hospital
were penicillin-resistant [7]. Currently, roughly 90% of
strains in the UK [8] and nearly all of those in the US
are resistant to penicillin, while in some communities
more than 50% of strains are resistant to methicillin [9].
Resistance among gram-positive organisms is familiar
territory. The arc of methicillin-resistant S. aureus
(MRSA) has been well documented in Europe and the US,
and the appropriate international reaction to its spread
in the 2000s has allowed for a relative plateau in the
prevalence of hospital-associated, if not yet community-
associated, strains in these countries (Figure 2). Although
still on the rise in some European and Asian countries
[10,11], vancomycin-resistant enterococci (VRE) have also
slowed their spread in North America in response to simi-
larly targeted infection control measures [12].
In contrast, the new landscape of resistant gram-
negative bacteria is unfamiliar and even more alarming.
Organisms producing extended-spectrum beta-lactamases
(ESBL) have increased their prevalence in Europe and
elsewhere [13,14], and in some areas are “crossing the
border” from hospital settings to the community. A recent
prospective surveillance study of 1,713 asymptomatic,
urban-dwelling volunteers in the Netherlands, frequently
referred to as a country with “little” AMR, revealed the
presence of ESBL-producing enterobacteriaceae in 8% of
stool samples; [15] this prevalence is only slightly lower
than that found in symptomatic patients of the same
region (10.6%) [16].
The emergence and rapid spread of carbapenemase-
producing gram-negatives such as extensively drug-resistant
Acinetobacter spp. and enterobacteriacae producing
New-Delhi metallo-protease-1 (NDM-1), Klebsiella pneumo-
niae carbapenemase (KPC), or oxacillinase 48 (OXA-48) are
disturbing, as these multidrug-resistant infections leave pa-
tients with few or no antimicrobial options. In March 2013,
the director of the US Centers for Disease Control and
Prevention (CDC) called a press conference to report that
these “nightmare bacteria," unseen in the country before
2001, had increased their prevalence fourfold in a mere dec-
ade. Invasive CRE infections carry mortality rates of 40 –
50% [17].
In the West at least, CRE appear to be largely confined
at present to the hospital setting, but a jump to the com-
munity, as seen with MRSA, is a real prospect for the
near term. A recent environmental point prevalence
study conducted by Walsh and colleagues in New Delhi,
India, revealed the presence of the NDM-1 gene in two
of fifty community drinking water samples and twelve of
Figure 2 Community-associated, hospital-associated, and overall MRSA prevalences in the United States from 1999 through 2010.
From the Center for Disease Dynamics, Economics and Policy (www.cddep.org).
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tion bias of data from the US and Europe likely creates a
distorted view of the current overall prevalence of and
mortality due to multi-resistant organisms. The burden
of drug-resistant infections in low-income countries is of
course difficult to quantify, but appears to be manifold
higher than those in high-income countries [19,20].
Organisms that are almost entirely community-acquired
such as Neisseria gonorrhoeae also continue to increase
their resistance. Once sensitive to penicillin, tetracycline
and fluoroquinolones, N. gonorrhoeae ’s current resistance
rates leave only ceftriaxone as viable therapy in many re-
gions [21]. Unfortunately, this treatment of last resort is un-
likely to hold: the H041 N. gonorrhoeae strain, which
carries high-level ceftriaxone and cefixime resistance, was
detected in Japan in 2011; [22] its phenotypic homologue,
F89, was isolated in France in 2012 [23].
The economic burden of AMR continues to climb.
The annual societal cost-of-illness for AMR is consid-
ered to be roughly $55 billion for the US alone [24],
though economists warn that this is likely an underesti-
mate. Based loosely on the “incremental” cost related to
the additional treatment of resistant over susceptible pri-
mary infection, this estimate masks the critical economic
burden that arises when resistance leads to the loss of
many of the advantages in medical care that antimicro-
bials have enabled [25]. It also excludes the indirect
costs of resistance, such as prolonged morbidity, reduced
productivity and related social effects. Studies of such
broad scope have yet to be undertaken.
Causes of antimicrobial resistance
The key promoter of antimicrobial resistance is the se-
lection pressure caused by the use of antimicrobials.
Overuse occurs across multiple ecosystems whose detailed
analysis is beyond the present scope. Here we focus on
antimicrobial consumption in humans and animals.Selection and transmission of resistant pathogens in humans
Physicians and other healthcare workers have contributed
to antimicrobial overuse through both omission and com-
mission. It is difficult for clinicians to place concerns re-
garding the general concept of AMR before the immediate
needs of the patient at point of care. Particularly in the out-
patient setting, the assumption among healthcare workers
that a patient expects an antimicrobial may be the most
important driver of antimicrobial over-prescription [26].
Meanwhile, those who have taken a more active stand
against AMR may have unwittingly exacerbated the
problem. Until very recently, guidelines recommended
unnecessarily long courses of antibiotics to avoid the de-
velopment of resistance among targeted organisms: [27]
Fleming’s warning was followed to the letter. But the
antimicrobial is agnostic of its target; prolonging its ad-
ministration prolongs the selection pressure favoring an
evolution toward resistance among all affected microbes.
More data are urgently needed on the optimal duration
of antimicrobial therapy for various types of infection to
better define instances where courses can be curtailed
without placing the individual patient at risk of relapse.
Once resistance has been selected for, rapid human-to-
human transmission of pathogens with resistant genes en-
ables their spread. Although awareness is increasing, basic
infection control measures such as hand hygiene are still
performed suboptimally in many settings [28]. Isolation and
cohorting measures are often delayed or altogether omitted
by delays in diagnosis or their high relative cost, respectively
[29]. Among other phenomena, globalization has enabled
“medical tourism,” which facilitates in unprecedented fash-
ion the international spread of resistance [30,31].
The role of antimicrobial consumption by food-producing
animals
Much focus has been placed on human antimicrobial
overconsumption as the main driver of AMR spread,
Huttner et al. Antimicrobial Resistance and Infection Control 2013, 2:31 Page 4 of 13
http://www.aricjournal.com/content/2/1/31likely because at present this is where the data are. But
the consumption of antimicrobials by food-producing
animals worldwide dwarfs that of humans, and the evi-
dence base on their overconsumption as a powerful
driver of AMR in humans and animals alike is growing
swiftly.
The European Union’s collective ban on the non-
therapeutic feeding of antibiotics of human importance
to farm animals began in 2006 [32]. But other regions
have not followed suit. The example from the US, a
country with more than 300 million human inhabitants
and over 10 billion food-producing animals, is particu-
larly disheartening. After decades of little oversight of
antimicrobial use in the agricultural industry, the Food
and Drug Administration (FDA) finally released aggre-
gate data in 2009 on sales of antimicrobials within the
agricultural sector [4]. The discovery that a staggering
80% of all antimicrobials are destined for food-
producing animals, and not humans, has prompted sev-
eral calls for more aggressive surveillance of agricultural
and veterinary practices [33,34].
Yet governmental response has been weak and indus-
try resistance strong. Pharmaceutical and agricultural
productions are not formally required to provide data on
antibiotic sales and practices (the figures released in
2009 were based on voluntary reporting), making it im-
possible to verify claims of judicious use in animals. Fur-
thermore, there is no agreement on definitions or
measures of “standard” use. It is known that antimicro-
bials are systematically placed in animal feed at low
levels for growth promotion, and typically at higher
levels for “metaphylaxis,” which is a euphemism for
over-treating large numbers of healthy animals.
The American example is playing out elsewhere.
Countries in regions such as East Asia, Southeast Asia
and South America are increasing their meat consump-
tion exponentially, while most have not yet established
mechanisms for the oversight of antimicrobial adminis-
tration to animals, let alone bans on non-therapeutic
applications.
Meanwhile, the evidence for the link between anti-
microbial administration to animals and microbial resist-
ance in humans is steadily increasing. In a 2011 study, a
high prevalence of ESBL-coding genes was found in re-
tail chicken meat (79.8%); genetic analysis showed that
the predominant ESBL-coding genes in chicken meat
and rectal swab specimens from humans of the same
geographic region were identical. The same genes were
also frequently found in human blood culture isolates
[35]. Other data clearly show that antibiotic administra-
tion to chickens leads to more ESBL-producing entero-
bacteriaceae in chicken meat, [36] and that in humans
such bacteria confer an increased risk of antibiotic fail-
ure and fatal infections [37]. A recent nested case-control study of more than 400,000 primary care pa-
tients from a single health care system in Pennsylvania
from 2005 to 2010 revealed exposure to crop fields
where swine manure was used as fertilizer as a signi-
ficant risk factor for both community- and health
care-associated MRSA strains [38], echoing previously
reported data from the Netherlands [39].
Steps forward: successful strategies
Several attempts have been made on local, regional and
international levels to staunch the spread of AMR, es-
sentially by (1) decreasing the human-to-human trans-
mission of resistant pathogens, (2) decreasing the
excessive consumption of antimicrobials, particularly
those with broad-spectrum antimicrobial activity and,
more recently, (3) facilitating the development of novel
antimicrobials [40,41]. All measures have met with vary-
ing success. Table 1 summarizes abstracts presented at
the 4th WHAIF; these provide novel information on
antimicrobial use and resistance, the emergence and
control of endemic resistance, and antimicrobial
conservation.
Strategies to reduce transmission
Reductions in human-to-human transmission of resist-
ant organisms have been well documented via both hori-
zontal and vertical measures [42]. Horizontal measures
are not pathogen-specific and include interventions such
as improved hand hygiene and enhanced environmental
cleaning, both of which have been shown to interrupt
pathogen transmission effectively [28,43,44]. Vertical mea-
sures are pathogen-specific and include targeted and uni-
versal screening upon hospital admission (e.g., MRSA,
ESBL-producing gram-negatives) with or without preemp-
tive isolation, often using novel molecular diagnostic tech-
niques for rapid pathogen detection [45]. The decline in
MRSA prevalence in many European countries over the last
half-decade attests to the success of these approaches [41].
Newer strategies include the development of vaccines
specifically targeting resistant organisms. OmpA and FepA,
two immunogenic proteins found in ESBL-producing K.
pneumoniae, were recently identified as promising vaccine
gene candidates [46]. A vaccine composed of the outer
membrane vesicles of Acinetobacter baumanii is currently
being tested in animal models and appears to provide pro-
tection against at least some pan-resistant strains [47].
Other strategies are more indirect. The cytokine
interleukin-12 (IL-12) is being tested as an “enhancer of
adaptive immunity” in murine models infected with
N. gonorrhoeae, which appears to suppress cell-mediated
immune responses in the host. Local treatment of the mice
with IL-12 generated gonococcus-specific immunoglobulin
G and led to faster clearance of infection and induced re-
sistance to reinfection, suggesting both a prophylactic and
Table 1 Summary of abstracts presented at the 2013 World Healthcare-Associated Infections Forum
I. Antimicrobial use and resistance
Author Short title Study design Setting Key findings
Balkhy et al. Susceptibility of isolates from







• Acinetobacter spp. was highly resistant
(70 – 90%) to all tested antimicrobials
including carbapenems (78% had four-class MDR)
• Klebsiella spp. had low (0 – 14%) resistance with no
detected MDR









• High swine exposure (residential proximity to CAFOs)
was associated with an increased risk of MRSA
colonization
Dantes et al. National burden of invasive




USA, 2011 • Compared to 2005, hospital-onset MRSA
infections decreased by 54%, but
community-associated infections remain stable
• Invasive MRSA infections are now more common
among persons in the community than hospitalized
patients
Datta et al. Quantifying MDRO exposure
from patients in a single








• Within a 5-year period, 1,198 patients with MRSA in a














• Healthcare-associated VRE colonization and infections
are increasing dramatically in Germany, particularly SSI
and primary BSI
• There is a belt of significantly higher VRE proportions
running through the middle of Germany
Gikas et al. Antimicrobial use and HAI






• 54.7% of hospitalized patients were receiving an
antimicrobial (a slight increase from 51.4% ten years
before)
• ICU and surgery patients received the highest
proportion of antimicrobials
• 9% of patients had documentation of a HAI
Gniadkowski
et al.




Poland, 2008 – June
2013
• KPC-producing enterobacteriaceae have spread rapidly
throughout Poland since their emergence in 2008
• Most common infection type is UTI; infections are most
commonly reported by ICUs






Taiwan, 2002 – 2011 • VRE infections in Taiwanese ICUs are increasing
dramatically
• ESBL-producing Escherischia coli infections have been
increasing in Asia Pacific
• Resistance to colistin (polymyxin B) is emerging in A.
baumannii and Pseudomonas aeruginosa
Kaku et al. Trends of antimicrobial





Japan, 2012 – April
2013
• ESBL-producing bacteria are increasing in prevalence











• Of 469 patients sampled on admission by rectal swab,
36% were positive for blaNDM and 92% for blaCTX-M-15
Reuland
et al.
Risk factors for carriage of
ESBL-producing enterobacteri-








• Of 1713 stool samples from community-
dwelling volunteers, 8% were positive for
ESBL-producing enterobacteriaceae
• Significant risk factors were hospital admission in a
foreign country, antimicrobial use, and antacid use
• ESBL-encoding genes CTX-M-15 and -14 were signifi-
cantly associated with travel to Africa and the Middle
and Far East, while CTX-M-1 had no association with
travel
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Thu le et al. Antimicrobial use and





• Antimicrobials are prescribed inappropriately in
Vietnamese surgical patients
• The chief reason for prolonging antimicrobial therapy
was the perception of a “poor environment”
II. Emergence and control of endemic resistance
Author Short title Study design Setting Key findings
Adler et al. Characteristics of an outbreak
caused by OXA-48-producing









• At the peak of the outbreak, one third of ICU patients
acquired OPE
• After the implementation of a bundled intervention,
which included cohorting colonized patients, frequent
rectal surveillance, and improving the implementation of
infection control practices, no new cases were detected
over the following three months
Baltieri et al. Prevention of Staphylococcus










• In response to increasing MRSA prevalence, universal
NICU screening and decolonization (nasal mupirocin
and oral hygiene with chlorhexidine for one week) were
implemented
• The fraction of MRSA infections decreased from 2% to
0.4% after bundle implementation; there was no
significant impact on MSSA infections
• There was no microorganism replacement
phenomenon
Cheung et al. Overcoming hand hygiene
fatigue by involving the link
nurses
Before-after study Tertiary care hospital,
Hong Kong,
2008 – 2012
• The activities of link nurses helped to increase









2010 – March 2013
• Incidence of secondary cases of VRE and CRE was
significantly lower if cohorting and dedicated nursing
staff and/or barrier precautions were employed within
two days of detection of the index case
• If these measures were delayed beyond two days, VRE
spread was more significant than that of CRE
Grall et al. Can the medical device
DAV132 decrease the impact






France, 2013 • DAV132 is an oral medical device designed to deliver
an adsorbent to the distal ileum that interferes with
antibiotic absorption distal to the ileocecal junction
• DAV132 captured gut antibiotic residues in dogs
treated with intravenous levofloxacin without impacting
blood pharmacokinetics and, in mice, significantly
reduced the impact of cefotaxime on resistance to
colonization by beta-lactam resistant enterobacteriaceae
III. Antimicrobial conservation




control strategies of MDR
infections in a neonatal ICU
Before-after study Neonatal ICU,
Malaysia,
2012 – April 2013
• An antimicrobial conservation program with
dedicated staff was implemented, with resultant
improvement in hand hygiene practices
(95% compliance) and a sharp decline in HAI sepsis rates
Bailin et al. Antimicrobial treatment for
UTI among patients with total







USA, 2011 – 2012
• Pre-operative screening for UTI was conducted in 95% of
patients undergoing total hip or knee arthroplasty,
regardless of symptoms; post-operative removal of the
urinary catheter was also followed by urinalysis in 99% of
patients regardless of symptoms
• Nearly half (45.5%) of patients received antimicrobials
pre- or post-operatively
• In the prospective study, receipt of antimicrobials was
not associated with signs and symptoms of UTI
Bavestrello
et al.





Chile, 2008 – 2009 • After regulations on antimicrobial use in the salmon
industry were introduced in late 2008, importation of
fluoroquinolones decreased dramatically
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Edmunds
et al.
Assessing the need for
antimicrobial use guidelines
among staff of a Saudi Arabian
hospital
Voluntary survey Tertiary care hospital,
Saudi Arabia, 2013
• Physicians’ responses to clinical vignettes in this survey
showed good awareness of appropriate antibiotic
options for various infections
• Correct answers were not associated with age group,
gender, or training status
Glass-Kaastra
et al.
Variation in antimicrobial use






• Although overall antimicrobial use is declining, patterns
of use vary by province







diseases in Latin America
International
guideline
Latin America, 2013 • This guideline was recently updated to include recent
surveillance data from Central and South America
Koo et al. Appropriateness of continued





• Only 37.8% of systemic vancomycin prescriptions for
339 hospitalized patients over the year were deemed
appropriate
Ling et al. Case-control study to








• Significant risk factors were overseas hospitalizations in











• Only 14% of hospitals responding to a ESCMID survey
reported having an ACP in place
• The new Infection Control Africa Network is
implementing ACP education programs in some African
countries; long-distance learning and communication
will employ mobile phone technology





Before-after study 17 hospitals, Italy
(Emilia-Romagna),
2011 – 2013
• Given the rapid spread of CRE in Italy, a bundled
intervention targeting patients at increased risk for CRE
was implemented in mid-2011 in the county of
Emilia-Romagna
• A significant deceleration in the spread of CRE was
observed overall; in 5 hospitals the incidence rate of
CPKP decreased from 32 to 15 cases/100,000 hospital
patient-days
Ndoye Antibiotic control in Senegal Before-after study Community
hospitals, Senegal,
2008 – 2012
• Despite a national initiative issued in 2008 to establish
site-based antibiotic conservation, regular assessments
through 2012 reveal that nearly 60% of facilities have
not begun any preparatory activity, and no facility has
implemented recommended interventions fully
• The chief reason appears to be a shortage of
dedicated human resources









• Engagement of internists and promoting infectious
diseases consultations were very effective; strategies
incorporating education, local guidelines, and feedback
were less so
• Specific programs to decrease UTI prophylaxis and









ICUs in a single
tertiary care center,
USA, 2009 – 2010
• Antibiotics were continued for more than 3 days in
patients without VAP (77%)
• Those patients with inappropriately long antibiotic





A multidisciplinary initiative to







• This alliance of nearly 500 individuals from 42 countries
was formed in 2011
• Non-profit organization composed of antimicrobial
prescribers (physicians, veterinarians) and consumers,
including politicians and environmentalists) open to all
people worldwide
• Goal is to decrease AMR’s prevalence
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Skov et al. Reducing antibiotic usage in







• In response to increasing AMR prevalence, a campaign
to reduce unnecessary antimicrobial consumption has
been launched
• The campaign targets prescribers (physicians) and
consumers (general public)
ACP: antimicrobial conservation program; AMR: antimicrobial resistance; BSI: bloodstream infections; CAFO: concentrated animal feeding operation; CDI: Clostridium
difficile infection; CRE: carbapenem-resistant enterobacteriaceae; ESBL: extended-spectrum beta-lactamase; ESCMID: European Society of Clinical Microbiology and
Infectious Diseases; HAI: healthcare-associated infection; ICU: intensive care unit; KPC: Klebsiella pneumoniae carbapenemase; LTCF: long-term-care facility;
MDR: multi-drug resistant; MDRO: multidrug-resistant organism; MRSA: methicillin-resistant Staphylococcus aureus; MSSA: methicillin-susceptible S. aureus; NICU: neonatal
intensive care unit; OPE: OXA-48-producing enterobacteriacae; SSI: surgical site infections; UTI: urinary tract infection; VAP: ventilator-associated pneumonia;
VRE: vancomycin-resistant enterococci.
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proaches make it to the clinic, however, their long-term ef-
ficacy will be no more absolute than that of the antibiotics
developed before them: the development of resistance is a
dynamic process.
Finally, it should be noted that morbidity and mortality
from infectious diseases were already declining sharply be-
fore the advent of antimicrobials and most vaccines: the
implementation of sewage systems more than halved child
mortality due to diarrheal illnesses by the early 20th cen-
tury in several European countries [49]. This backbone of
public health is now more critical than ever; effective sani-
tation systems worldwide are needed to decrease trans-
mission of resistant microbes via wastewater.
Strategies to reduce consumption
Many hospitals employ antimicrobial conservation (AC)
programs (traditionally known as antibiotic stewardship
programs) to optimize both inpatient and ambulatory
antimicrobial prescription practices. Several studies have
documented an overall effectiveness of conservation pro-
grams with regard to this specific goal [50-54]. Much ef-
fort is now being expended to identify more specifically
the obstacles to and facilitators of successful programs.
Unfortunately, the reach of AC is limited. Worldwide, the
vast majority of healthcare settings have not implemented
AC programs. And in those countries with a relatively
strong AC presence, most programs are found only in
acute-care facilities, while evidence mounts that chronic-
care facilities such as nursing homes and rehabilitation
units, where prescription practices are largely unregulated,
constitute equally important reservoirs of resistance [55].
And while AC can be linked to reductions in over-
prescription, studies linking AC initiatives directly to re-
ductions in AMR prevalence are still lacking.
Nonetheless, one clear benefit of system-wide AC
programs is a subsequent reduction in symptomatic
Clostridium difficile infections (CDI). Among other ini-
tiatives, the substantial decrease in fluoroquinolone and
cephalosporin prescribing in the United Kingdom has
led to a 70% reduction in symptomatic CDI over the
past five years [56]. Indeed, CDI has become a driver for
AC programs in some healthcare settings.In the community, several landmark national campaigns
appear to have achieved considerable success in reducing
antimicrobial prescription. Campaigns attempt to educate
not only healthcare professionals (antimicrobial pre-
scribers), but also the general public (antimicrobial con-
sumers) on the dangers of excessive antimicrobial usage;
the latter appear to be particularly effective. France’s na-
tional campaign from 2002 to 2007 reduced the total
number of antibiotic prescriptions per 100 inhabitants
by 26.5% overall, with the greatest reduction (35.8%) in
antibiotic consumers aged 6–15 years old [57]. Belgium’s
national campaigns from 1999 to 2010 reduced the total
number of antibiotic packages per 1000 inhabitants from
3.6 in 1999–2000 to 2.4 in 2009–2010 (a 33% reduction).
S. pneumoniae resistance to penicillin decreased from 18%
in 2000 to 7% in 2009. The total cost for reimbursement
of antibiotics decreased by 21 million euros (−16.7%) from
125.5 million in 2002–03 to 104.5 million in 2008–09; cu-
mulative savings in this period were thus 90 million euros
(two thirds were due to reduced prescribing; one third was
due to a reduction in the price of antibiotics). Because the
costs of the six campaigns between 2002 and 2009 was 2.4
million euros, for every euro invested in the campaign, 25
were saved (H. Goossens, unpublished data).
And when a campaign is bolstered by concomitant
governmental action, results can be impressive. In 1998,
the Chilean Ministry of Health proactively enforced
existing laws restricting the sale of antimicrobial agents
without a medical prescription. These regulatory mea-
sures had a sustained impact on antimicrobial use in the
outpatient setting: sales of oral agents decreased by
nearly half within a few years [58].
What is yet unclear, however, is the durability of such
measures; a rebound rise in antimicrobial prescription
may occur once a campaign, or a strict enforcement of
existing regulations, is brought to a close. For the mo-
ment, at least, outpatient antimicrobial usage in North
American, European, and some other countries appears
to be on a modest decline (Figure 3).
As with AMR prevalence data, however, the view from
Europe and North America may provide an overly san-
guine impression of reduction rates in both antimicrobial
consumption and resistance transmission. Antimicrobial
Figure 3 A decline in human per capita outpatient antibiotic use in North America and France has been documented over the past
decade. From the Center for Disease Dynamics, Economics and Policy (www.cddep.org).
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sentially non-existent in many developing nations, where
antimicrobial consumption data are lacking though, para-
doxically, easy access to mass-produced, sometimes di-
luted (subtherapeutic) antimicrobials often is not.
Efforts to reduce antimicrobial consumption in food-
producing animals date from as early as 1969, with
Swann’s recommendation calling for a ban on the non-
therapeutic use of antimicrobials in animals and agricul-
ture in the United Kingdom [59]. Such a ban was highly
contentious then, as now, and obstacles to its implemen-
tation are abundant in numerous countries.
Facilitating the development of novel antibiotics
Efforts are under way in some Western nations to fast-
track the development of desperately needed novel antimi-
crobials. The research and development required to bring
one antimicrobial successfully to market can exceed 1 bil-
lion, thus many in the pharmaceutical industry have prior-
itized drugs with a wider market and indications for
long-term usage. A few public-private partnerships have
been established, among them the Innovative Medicines
Initiative (IMI), a joint undertaking between the European
Commission and the pharmaceutical industry. The IMI
acts as a neutral third party by supporting collaboration
among experts from industry and academia, and seeks
to accelerate antimicrobial discovery and developmentspecifically by exploring effective incentives via economic
models. In the US, the GAIN (Generating Antibiotic
Incentives Now) Act went into effect in late 2012; it
earmarks novel antibiotics for priority FDA review and
mandates the creation of a pathogen-focused (rather
than anatomic infection site-focused) antibacterial drug-
development pathway, thus attempting to reduce financial
impediments to drug development.
Beyond the clinic
Globalization and current widespread agricultural prac-
tices prevent hospitals and patients from existing in a se-
cure void. These external realities can quickly upend the
benefits accrued by years of methodical AC and infec-
tion control measures in any one hospital, as demon-
strated by the events following the admission of a sole
patient harboring a carbapenemase gene to a US hospital
[60].
Clinical interventions remain crucial, but they cannot
suffice in the face of AMR’s current magnitude and cross-
disciplinary complexity. Wide-ranging and highly coordi-
nated efforts on several societal levels are imperative to
slow the course of AMR. Policies requiring the tracking of
antimicrobial dispensing in humans and animals are ur-
gently needed. Data sharing and harmonization across na-
tional borders and industrial sectors, including pharma
and biotechnology, are essential. Table 2 lists the ten most
Table 2 The ten most urgent priorities for action against
the spread of antimicrobial resistance cited by
participants of the 4th WHAI Forum
For policy-makers and health authorities:
1 Limit the use of antimicrobials in food-producing animals by
banning non-therapeutic applications, including growth promotion
and metaphylaxis
2 Establish and enforce regulations on sales of antimicrobials for use
in human medicine, including prohibition of over-the-counter sales
worldwide
3 Develop a detailed charter on antimicrobial conservation to be
ratified and upheld by ministries of health worldwide
4 Develop coordinated and culturally sensitive awareness campaigns
targeting the general public and imparting the importance of
protecting antimicrobials as a limited and non-renewable resource
5 Rigorously support the improvement of sanitation systems to
eliminate resistant microbes in wastewater; regularly provide
education about fundamental practices such as hand hygiene to
prevent the spread of infection
6 Together with the pharmaceutical industry, explore (1) incentives to
stimulate research and fast-track development of novel antimicrobials
and (2) new economic models that reconcile public health interests
with industry profitability
For the human and veterinary healthcare communities:
7 Establish standardized, universal methods and metrics for
surveillance of antimicrobial use and resistance development,
respectively
8 In medical and veterinary school curricula, require universal and
detailed instruction in microbial resistance development and the
prudent use of antimicrobials; for physicians and veterinarians in
training, require on-the-job refresher courses
For the general public:
9 Include patients and other antimicrobial consumers in the
development and implementation of action plans
For industry:
10 Continue to develop and advance point-of-care rapid diagnostic
tests to avoid the prescription of antibiotics for viral infections and
allow more targeted therapy
Huttner et al. Antimicrobial Resistance and Infection Control 2013, 2:31 Page 10 of 13
http://www.aricjournal.com/content/2/1/31urgent priorities for action cited by participants of the
4th WHAI Forum; these address policy-makers, industry
leaders, and researchers alike.
Such measures will allow researchers and policy-makers
to define more clearly the global clinical burden of AMR.
This burden needs precise definition for several reasons,
among them: (1) society’s finite resources for confronting
AMR will be utilized more efficiently if they can be di-
rected where most needed, (2) such “hard” data would
swiftly repudiate the claim from certain industrial sectors
that regulation of antimicrobial administration to food-
producing animals and other like-minded measures are
unnecessary because AMR’s present clinical impact is lim-
ited, (3) a growing awareness of the true dimensions of
AMR’s global burden may effect a genuine paradigm shift
[61] in society’s collective consciousness, such that antimi-
crobials may finally be viewed by the majority (and not
simply by a small group of healthcare workers) as a non-renewable and highly endangered resource, thus placing
AMR in a context of sustainable development.
Though the most abstract, this third hypothetical con-
sequence could prove to be one of the most powerful el-
ements of a future impact on AMR’s course. Currently, a
near tragedy of the commons is playing out: individuals
who benefit from a shared resource are effecting the
rapid depletion of that resource through independent
and rational action according to individual self-interest
[62]. But most individuals do not yet perceive antimicro-
bials as a limited resource. It is hoped that if and when
they do on a mass level, they will cooperate to support
implementation of measures protecting the resource and
thus the larger group’s long-term best interests.
By definition a paradigm shift is not reversible; indeed,
any global perception of antimicrobials as a shared and
endangered resource must be enduring. Evidence from
the laboratory does not support the hypothesis that all
microbes must pay a physiologic price for their acquired
resistance, rendering them less “fit” than their wild-type
counterparts [63]. That is, multi-resistant pathogens are
here to stay, whether we achieve temporary or even last-
ing reductions in antimicrobial overuse or not.
An urgent need for international collaboration
There are indications that this awareness may be taking
firmer root, and perhaps in places where it is currently
most crucial. Though the Indian government’s immedi-
ate reaction to the publication of the Walsh study in
2011 was to forbid the transfer abroad of any additional
Indian environmental specimens, this mandate has since
been reversed, and official governmental support has
been extended to the Indian medical societies’ recent
Chennai Declaration, a call to action against the further
spread of AMR [64].
Because of the tireless efforts of practitioners and re-
searchers from both non-governmental (e.g., the Center
for Disease Dynamics, Economics and Policy; the Alliance
for the Prudent Use of Antibiotics; and the World Alliance
Against Antibiotic Resistance) and governmental organi-
zations (e.g., the United Kingdom’s Chief Medical Officer,
Dame Sally Davies), an awareness of the scope of AMR is
beginning to reach non-clinical and non-academic sectors.
In 2012, Margaret Chan, Director General of the World
Health Organization declared publicly that AMR could
bring about “the end of modern medicine as we know it.”
[65] The American CDC recently released its first-ever re-
port on AMR, entitled “Antibiotic Resistance Threats in
the United States, 2013”; in his foreword, director Thomas
Frieden identified AMR as one of the nation’s most serious
health threats [66].
These calls to action should, at least theoretically, ac-
celerate the international collaboration urgently needed
to confront a global menace. Such may be happening,
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science ministers identified AMR as the “major health se-
curity challenge of the 21st century” and pledged intensive
international collaboration to achieve the concrete goals
of (1) avoiding the misuse of remaining antimicrobials and
(2) streamlining and facilitating the development of new
antimicrobials as well as (3) rapid diagnostics to accelerate
the identification and treatment of resistant pathogens
[67]. The formulation of such specific targets is encour-
aging: in recent decades the international community has
been long on general rhetoric and short on coordinated,
precise action.
Conclusion
Antimicrobial resistance is a clear and present danger.
Immediate and coordinated measures must be taken
worldwide to safeguard remaining antimicrobials and fa-
cilitate the development of novel antimicrobials. Bans on
nontherapeutic antimicrobial consumption in livestock
must be effectively championed despite strong resistance
from industrial sectors. Conservation programs must be
further optimized and implemented in other, non-acute
healthcare settings such as long-term-care facilities. Edu-
cational programs targeting both antimicrobial pre-
scribers and consumers must be further developed and
supported. The general public must continue to be made
aware of the current scale of AMR’s threat. International
collaboration among researchers and policy-makers
must solidify to effect lasting reductions in the spread of
antimicrobial resistance.
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